Co-Diagnostics Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

CODX$0.32+24.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Three Months Ended March 31,
	2024	2023
Product revenue	$252,745	$601,957
Grant revenue	215,109	-
Total revenue	467,854	601,957
Cost of revenue	234,505	502,241
Gross profit	233,349	99,716
Operating expenses
Sales and marketing	1,563,682	1,706,331
General and administrative	2,918,803	3,013,965
Research and development	5,679,678	5,014,060
Depreciation and amortization	330,573	316,010
Total operating expenses	10,492,736	10,050,366
Loss from operations	(10,259,387)	(9,950,650)
Other income, net
Interest income	362,733	202,372
Realized gain on investments	228,070	418,082
Gain on remeasurement of acquisition contingencies	450,260	1,037,672
Gain (loss) on equity method investment in joint venture	(70,955)	277,322
Total other income, net	970,108	1,935,448
Loss before income taxes	(9,289,279)	(8,015,202)
Income tax provision (benefit)	22,764	(2,259,811)
Net loss	$(9,312,043)	$(5,755,391)
Other comprehensive loss
Change in net unrealized gains on marketable securities, net of tax	79,855	178,621
Total other comprehensive income	$79,855	$178,621
Comprehensive loss	$(9,232,188)	$(5,576,770)
Loss per common share:
Basic and Diluted	$(0.31)	$(0.20)
Weighted average shares outstanding:
Basic and Diluted	29,842,874	29,483,540

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.